Kopran Limited is an India-based pharmaceutical company. The Company is primarily engaged in the business of manufacturing of formulation (finished dosage form) and active pharmaceutical ingredients (API). Its formulations product categories include penicillin-based finished oral dosage forms and non-penicillin-based finished oral dosage forms. The Company's penicillin-based finished oral dosage forms include amoxycillin, ampicillin, cloxacillin, amoxy clauv, flucloxacillin, and phenoxy methyl penicillin. Its non-penicillin-based finished oral dosage forms include macrolides, cardiovascular, anti-helmentics, antihistamine, anti-diabetic, pain management, gastroenterology, and respiratory. It has a portfolio, producing over 100 dosage forms. These include tablets, capsules, dry powder, suspension and injectables. Its subsidiary, Kopran Research Laboratories Ltd, manufactures a range of APIs, including Atenolol and Sterile Carbapenems.As of 14 Jun 2026, Kopran share price is ₹183.00. The stock opened at ₹177.89, compared to its previous close of ₹177.80. During today's trading session, Kopran share price moved in the range of ₹177.00 to ₹183.00, with an average price of ₹180.00 for the day. Looking at its last 52-week, the stock has touched a low of ₹177.00 and a high of ₹183.00. On the performance front, Kopran share price has increased by 38.82% over the last six months and is down 9.83% on a year-on-year basis.
The market capitalization of Kopran is ₹876 Crs, with a P/E ratio of 34.0 and a dividend yield of 1.65%.